Sanara MedTech Inc. — Form 8-K Summary
Report date: September 30, 2026. The filing reports the results of Sanara’s special shareholder meeting and an update on regulatory review of its proposed merger with MiMedx Group, Inc. It does not provide quarterly or annual financial results.
Shareholder vote
As of the September 1, 2026 record date, 9,188,035 common shares were outstanding, each entitled to one vote. Holders of 6,411,427 shares (approximately 69.78%) were present or represented, establishing a quorum.
| Proposal | For | Against | Abstain | Outcome |
|---|---|---|---|---|
| Approve and adopt the merger agreement | 6,372,989 | 1,944 | 36,494 | Approved |
| Advisory approval of merger-related executive compensation | 5,841,470 | 75,247 | 494,710 | Approved |
The proposal to adjourn the meeting to solicit additional votes was not submitted because sufficient votes were cast to approve the merger agreement.
Merger and regulatory update
Under the July 29, 2026 merger agreement, MiMedx’s wholly owned subsidiary is to merge into Sanara, with Sanara surviving as a wholly owned MiMedx subsidiary. Shareholder approval is secured, but the merger remains subject to satisfaction or waiver of the other agreement conditions.
MiMedx and Sanara initially filed their Hart-Scott-Rodino notifications on August 12, 2026. MiMedx, in consultation with Sanara, withdrew and refiled its notification on September 15 to allow the Federal Trade Commission additional review time. The resulting waiting period was scheduled to expire at 11:59 p.m. Eastern Time on October 15, 2026, unless extended or terminated earlier.
Financial condition and outlook
This 8-K does not report revenue, profit, cash flow, margins, debt, liquidity, financial guidance, or other operating metrics. The filing text does not provide a clear value for any of these measures.
Important facts for investors to verify
- Whether the HSR waiting period expired, was extended, or was terminated, and whether any other regulatory approvals are required.
- Whether all remaining merger conditions were satisfied or waived and whether the merger closed.
- The merger consideration, timing, and other transaction terms in the merger agreement and proxy statement; these details are not provided in this filing text.
- Any subsequent company filings reporting financial results or material developments.